"Everyone near me is running $9 Botox. Do I have to match it?"
No. Match the discount and you buy a patient who belongs to whoever is cheapest next month, and you teach the patients already on your books that your real price was never real.
The money in aesthetics is not at the bottom of the market. Published industry benchmarks consistently show the top of the market earning multiples of the median per location, and the gap tracks pricing and service mix more than patient volume. The top of the market is pulling away, and it is not doing it on volume.
And this is happening in a growing market, not a shrinking one. The American Med Spa Association reports average annual medical spa revenue rose to $1,398,833 in 2024 from $1,307,587 in 2023, even as the number of spas increased. Med spa location count grew 18% in 2025 according to Zenoti's benchmark.
So discounting is not a survival response. It is a positioning decision, and most owners make it without realising that is what they are deciding.
What a discount tells a patient choosing someone to inject their face
Price is the loudest piece of information on your page. For a cash-pay patient who has never met you, it is often the only piece of information she can interpret with confidence.
When your toxin is priced at the bottom of your market, she does not conclude that you are generous. She runs through a short list of explanations: you are new, you are quiet, you are overstocked, or you are not as good as the clinic charging more. Researchers have studied whether daily deal adoption correlates with small business failure, using business survival data. That is a question about companies, not about patients, but the inference a careful patient makes on her own runs along the same line.
The gap between discount and premium pricing is not a rounding error. Per-unit toxin and per-syringe filler pricing varies widely by market, and a premium practice is not sitting a few percent above the discounters. It is in a different band entirely. No one persuades a patient across that gap in a consult. It is bought in advance with proof.
There is a second audience you forget about. Every existing patient who paid your full price and then sees 50% off in her feed has just been told what she really should have paid. Zenoti's guidance makes the same point, and warns that deal-site patients carry the lowest lifetime value of any acquisition channel, with only 10 to 20% converting to full price. That is vendor guidance rather than independent research, so weigh it accordingly, but it matches what practice owners describe.
Stop measuring cost per lead. Measure value by the offer that bought the patient
Here is the honest state of the evidence on deal-driven patients. The study everyone quotes is old and it is not from aesthetics. Utpal Dholakia's work at Rice University is the most-cited source. In a survey of 324 businesses that ran a daily deal between August 2009 and March 2011, 55.5% reported making money, 26.6% lost money and 17.9% broke even. Close to 80% of deal users were new customers, but only 35.9% spent beyond the deal's value and 19.9% returned to buy at full price. A separate year-long survey of 150 businesses running Groupon promotions between June 2009 and August 2010 found the promotion profitable for two thirds, while almost half of restaurants found it unprofitable. A single-company case study pointed the other way: about 4% of that company's Groupon users came back for at least a second purchase and spent more than the average full-price customer when they did, and the business earned revenues almost 140% higher than it would have without the promotion.
That is dated, cross-industry data, and the researchers' own conclusion is that daily deals can work for some businesses and are not a one-size-fits-all tool. Which is precisely why you should stop arguing about national statistics and measure your own.
Do this, and most practices can do it inside their existing patient software in an afternoon:
- Tag every new patient with the offer that acquired her. Full price, intro offer, deal site, event, referral, membership.
- Wait twelve months, or look back twelve months if your records allow it.
- Compare four things by cohort: 12-month revisit rate, total revenue per patient, rebook rate at the end of a visit, and the percentage who ever bought anything at full price.
Cost per lead will tell you the discount cohort was cheap to acquire. Revenue per patient at twelve months usually tells you a different story. Decide on the second number. We build this cohort view into reporting for the practices we work with, because an acquisition channel that looks efficient at the top of the funnel and empty at the bottom is the most expensive mistake in aesthetics.
The four places value is built before price is ever mentioned
If the price conversation feels like a fight, the problem is almost never the price. It is that nothing before it earned the number. Four touchpoints do that work.
The website. A premium price needs a premium frame. Slow pages, stock photography, a generic template and a form that nobody answers for two days all quietly price you down before a patient reaches your fee schedule. The site is where a stranger decides what league you are in.
The before and after proof. This is the single highest-leverage asset in an aesthetic practice and the most commonly neglected. Not a grid of tiny squares. Consistent lighting, consistent angles, interactive sliders, results on faces that look like the patient looking at them, organised by the treatment and the concern she actually searched for. Proof is what closes the gap between you and the cheap clinic. Persuasion does not.
The consult script. A discounting market sells units. A premium practice sells a plan. The consult should move from "what does Botox cost here" to "here is the result we are building, here is the sequence, here is what maintenance looks like across the year, here is the total investment." The patient cannot comparison-shop a plan against a per-unit price, because they are not the same product.
The follow-up. Most practices lose the patient in the silence after the consult. Automated email and SMS follow-up with the specific proof relevant to her concern, a clear path back to booking, and a reactivation sequence for patients who have drifted is where consults become bookings without a single discount being offered.
Fix those four and price objections thin out on their own.
When a price-led offer is the right call
Never discounting is absolutism, and owners rightly ignore absolutists. There are four situations where a price-led offer is the correct commercial decision:
- A new device. You need volume, photographs and early reviews quickly. Introductory pricing buys a results library, which is a durable asset.
- A dead weekday. Capacity you will never sell is worth more sold at a discount than empty. Make it time-bound and name it as such.
- A new injector's book. Launch pricing fills a diary, builds confidence and generates proof. It expires when the diary is full.
- A new practice opening. Opening pricing is understood by patients as an opening, not as your standing position.
The common thread: the discount is tied to a reason and an end date, it never becomes the headline price, and it is never your flagship treatment in your flagship channel.
Bundle the outcome, not the price
The way to give a patient more value without lowering your number is to sell a larger, better-designed thing.
Treatment plans that bundle a sequence of visits toward a stated outcome, with a modest bundle discount against buying each visit separately, keep your per-unit price intact while raising ticket size and visit frequency. A modest bundle discount, in the region of 10 to 15%, is the common working ceiling before margin erodes, and monthly memberships typically pair an included treatment credit with a standing discount on injectables.
Both structures do what a discount cannot. They buy frequency and loyalty rather than a single transaction, and they move a patient from shopping each appointment to belonging to your practice. Med spa membership sales grew 13% year over year in the same Zenoti data, which is the direction the market is already moving.
Holding price is not stubbornness. It is a system: a site that looks like what you charge, proof that makes the number obvious, a consult that sells a plan, and follow-up that does not let a warm patient go cold. That system is what we build for aesthetic practices, and if yours is carrying the whole weight of the price conversation at the consult, a free 15 minute discovery call is a good place to start.
Frequently asked questions
Should I match a nearby clinic running $9 per unit Botox?
No, not as a standing price. The gap between discount and premium positioning is a different league of pricing, not a few percent, and you do not close it by meeting them in the middle. You close it with proof, a consult that sells a plan rather than units, and follow-up that converts the patients already interested in you.
Is there hard evidence that discount patients come back less often?
The most-quoted research is from Rice University around 2010 and 2011 and is cross-industry rather than aesthetics-specific. In one company case study about 4% of Groupon users returned for a second purchase and those users brought in less than half the revenue of full-price customers. Treat it as suggestive and measure your own practice instead, by comparing 12-month revisit rate and revenue per patient across cohorts tagged by the offer that acquired them.
How do I actually measure whether a special was worth running?
Tag every new patient with the offer that acquired her, then look at four numbers twelve months later: revisit rate, total revenue per patient, rebook rate at the end of a visit, and the share who ever paid full price. Cost per lead will almost always flatter the discount. Revenue per patient at twelve months is the number that should decide it.
When is running a discount actually the right move?
Four situations: introducing a new device where you need results photographs fast, filling a weekday that would otherwise sit empty, launching a new injector's book, and opening a new practice. In all four the offer is tied to a reason and an end date, it never becomes your headline price, and it is not your flagship treatment in your flagship channel.
What can I offer instead of cutting my treatment prices?
Bundle the outcome and the visit frequency rather than the price. Treatment plans across a sequence of visits and monthly memberships keep your per-unit number intact while raising ticket size and loyalty. A bundle discount in the region of 10 to 15% is the common working ceiling before margin erodes, and memberships usually include a monthly treatment credit.
